AbbVie Reports Third-Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Abbvie (ABBV) PT Lowered to $71 at BMO Capital
November 5, 2018 8:47 AM ESTBMO Capital analyst Alex Arfaei lowered the price target on Abbvie (NYSE: ABBV) to $71.00 (from $78.00) while maintaining a Underperform rating.
The analyst commented, "3Q18 was fine, but not great; particularly the Imbruvica beat. The market is ignoring management's long-term guidance, and signals of... More
AbbVie (ABBV) Tops Q3 EPS by 12c, Lifts FY EPS Guidance
November 2, 2018 7:48 AM EDTAbbVie (NYSE: ABBV) reported Q3 EPS of $2.14, $0.12 better than the analyst estimate of $2.02. Revenue for the quarter came in at $8.24 billion versus the consensus estimate of $8.22 billion.
GUIDANCE:
AbbVie sees Q4 2018 EPS of $7.90-$7.92, versus the consensus of $7.88.
For earnings history and earnings-related data on AbbVie (ABBV) click here.
... More